GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pharmagreen Biotech Inc (OTCPK:PHBI) » Definitions » 9-Day RSI

Pharmagreen Biotech (Pharmagreen Biotech) 9-Day RSI

: 49.50 (As of Today)
View and export this data going back to 2008. Start your Free Trial

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.

As of today (2024-04-19), Pharmagreen Biotech's 9-Day RSI is 49.50.

The industry rank for Pharmagreen Biotech's 9-Day RSI or its related term are showing as below:

PHBI's 9-Day RSI is ranked worse than
68.37% of 1138 companies
in the Drug Manufacturers industry
Industry Median: 42.395 vs PHBI: 49.50

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Pharmagreen Biotech's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmagreen Biotech 9-Day RSI Distribution

For the Drug Manufacturers industry and Healthcare sector, Pharmagreen Biotech's 9-Day RSI distribution charts can be found below:

* The bar in red indicates where Pharmagreen Biotech's 9-Day RSI falls into.



Pharmagreen Biotech  (OTCPK:PHBI) 9-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharmagreen Biotech  (OTCPK:PHBI) 9-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.


Pharmagreen Biotech 9-Day RSI Related Terms

Thank you for viewing the detailed overview of Pharmagreen Biotech's 9-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmagreen Biotech (Pharmagreen Biotech) Business Description

Traded in Other Exchanges
N/A
Address
112 North Curry Street, Carson, NV, USA, 89703
Pharmagreen Biotech Inc is a biotech science company with specialized products and services in the cannabis industry. The company plans to produce and sell tissue culture plantlets and cannabis oil. Its line of nutraceutical products is a proprietary blend of therapeutic plants and mushrooms. It is developing its business model beyond just cannabis, and is focused on near term revenues from its proprietary blend of therapeutic plants and fungi, a nutraceutical wellness product. Utilizing the Company's expertise in plant genetics, Its transgenic program uses the newest technology available to research and create nutraceuticals, protein-based vaccines, and daily supplements with the potential to improve lives and address a wide variety of disease conditions.